Purchase this article with an account.
H. Fujishima, A. Igarashi, N. Okada, Y. Takano, M. Tanaka, N. Asano-Kato, M. Miyake-Kashima, K. Fukagawa; PGD2 Concentration in Tears of Patients With Severe Allergic Conjunctival Diseases . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3746.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Type I allergic reaction has two phases; the early phase and late phase. The late phase reaction is thought to be involved in the pathogenesis of cobblestone-like papillae and corneal lesions in severe allergic conjunctival diseases. PGD2 is known to play an important role in the pathogenesis of ocular allergic reactions. The purpose of this study is to investigate a possible relationship between the concentration of PGD2 and the severity of ocular allergic disease and also to assess the effect of treatment on its concentration. Method: Twenty patients with severe ocular allergic disease with cobblestone-like conjunctival papillae and corneal ulcers, and 8 normal volunteers were enrolled in this study. Tears were collected by micropipette and PGD2 was measured by EIA. Results: Mean concentration of PGD2 in tears from normal volunteers was 20.9±4.8 (mean±SE) pg/ml. It was significantly increased to 644.3±198.9 pg/ml in patients (p=0.02; t-test). We also compared the PGD2 concentration in 7 very severe patients before and after treatment by surgical conjunctival papillary excision. Corneal lesions improved dramatically in these 7 patients. PGD2 in tears was 1068.7±207.3 pg/ml before treatment and decreased significantly to 259.9±111.6 pg/ml (p=0.005) one week after excision. Conclusion: PGD2 is highly detected in tears of patients with severe ocular allergic disease and this concentration was decreased by the treatment. PGD2 may play an important role in the pathogenesis of severe ocular allergic disease.
This PDF is available to Subscribers Only